Advertisement

Topics

CryoLife Inc. Company Profile

15:35 EDT 24th September 2017 | BioPortfolio

Founded in 1984, CryoLife was the first company to commercially develop the ultra-low temperature preservation of viable human heart valves for transplant. Since then, we have been engaged in an exciting transfer of technology which has led to the highly successful preservation of human saphenous and femoral veins as well as orthopaedic tissues such as tendons, menisci, and osteo-articular cartilage grafts. Today, the company holds thirteen exclusive cryopreservation patents, including the CryoSafe® triple pouch packaging system (patent #no. 5,031,762) designed to withstand ultra-cold temperatures and allow for aseptic introduction of the allograft into the sterile field.
Our laboratories and research facilities, located in suburban Atlanta, Georgia, have been designed to maximize the quality of our tissues and services. Tissue processing is conducted in a class 100 clean room environment by CryoLife technicians trained in microsurgical techniques. An in-house microbiology department performs extensive testing on each type of tissue for bacterial and fungal contamination. All donors are screened according to FDA regulations.

Our quality management system has been awarded the coveted ISO certification, an internationally recognized sign of quality assurance excellence. As a company, we are wholly committed to advancing the evolution of tissue preservation and engineering technology.

Location

1655 Roberts Blvd., NW
Kennesaw
Georgia
30144
United States of America

Contact

Phone: 770.419.3355
Fax: 770.426.0031
Email: info@cryolife.com


News Articles [9 Associated News Articles listed on BioPortfolio]

CryoLife to Present at 37th Annual Canaccord Genuity Growth Conference

ATLANTA, Aug. 2, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in th...

CryoLife to Present at Two Investor Conferences in September 2017

ATLANTA, Sept. 18, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that Pat Mac...

CryoLife Announces Release Date and Teleconference Call Details for 2017 Second Quarter Financial Results

ATLANTA, July 10, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2017 second quarter financial...

CryoLife to Present at Upcoming Investor Conferences in New York

ATLANTA, Nov. 3, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that Steven G. Anderso...

CryoLife Announces Release Date and Teleconference Call Details for 2011 Fourth Quarter and Year End Financial Results

ATLANTA, Feb. 2, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that 2011 fourth ...

CryoLife's (CRY) CEO Pat Mackin on Q2 2017 Results - Earnings Call Transcript

CryoLife Reports Second Quarter 2017 Financial Results

ATLANTA, July 24, 2017 /PRNewswire/ -- Second Quarter Highlights: Revenues Increased Two Percent Year-over-Year to $47.8 Million; Non-GAAP Revenues Increased Four Percent Year-over-Year...

Global Tissue Engineering Market Research 2011 2022 [Report Updated: 19042017] Prices from USD $2240

SummaryThe Global Tissue Engineering market is estimated to reach 13.9 Billion USD in 2017. The objective of report is to define, segment, and project the market on the basis of type, application, and...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

CryoLife, Inc.

CryoLife Inc.

Founded in 1984, CryoLife was the first company to commercially develop the ultra-low temperature preservation of viable human heart valves for transplant. Since then, we have been engaged in an excit...

More Information about "CryoLife Inc." on BioPortfolio

We have published hundreds of CryoLife Inc. news stories on BioPortfolio along with dozens of CryoLife Inc. Clinical Trials and PubMed Articles about CryoLife Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CryoLife Inc. Companies in our database. You can also find out about relevant CryoLife Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...


Corporate Database Quicklinks



Searches Linking to this Company Record